Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by First Turn Management LLC

First Turn Management LLC decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 7.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 647,611 shares of the company’s stock after selling 55,787 shares during the quarter. Mirum Pharmaceuticals makes up approximately 4.0% of First Turn Management LLC’s portfolio, making the stock its 4th largest holding. First Turn Management LLC owned 1.36% of Mirum Pharmaceuticals worth $25,257,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Quest Partners LLC raised its position in shares of Mirum Pharmaceuticals by 7,513.3% in the second quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares during the period. Amalgamated Bank raised its position in shares of Mirum Pharmaceuticals by 60.8% in the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the period. ProShare Advisors LLC bought a new position in shares of Mirum Pharmaceuticals in the second quarter valued at approximately $213,000. Finally, Creative Planning bought a new position in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $249,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Evercore ISI lifted their price target on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Thursday, August 8th. Cantor Fitzgerald boosted their target price on shares of Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Citigroup boosted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Leerink Partners boosted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Ten research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $57.73.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $41.42 on Tuesday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The company’s fifty day moving average price is $40.13 and its two-hundred day moving average price is $36.26. Mirum Pharmaceuticals, Inc. has a 52-week low of $23.14 and a 52-week high of $48.89.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter in the previous year, the company earned ($0.57) EPS. The firm’s revenue for the quarter was up 89.4% compared to the same quarter last year. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.51 earnings per share for the current year.

Insider Activity

In other news, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $47.10, for a total value of $117,750.00. Following the sale, the senior vice president now owns 2,426 shares in the company, valued at approximately $114,264.60. The trade was a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.